RAPAMYCIN: CLINICAL RESULTS AND FUTURE OPPORTUNITIES1
- 1 October 2001
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Transplantation
- Vol. 72 (7), 1181-1193
- https://doi.org/10.1097/00007890-200110150-00001
Abstract
No abstract availableThis publication has 78 references indexed in Scilit:
- Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progressionClinical Biochemistry, 1998
- Rapamycin Inhibition of the G1 to S Transition Is Mediated by Effects on Cyclin D1 mRNA and Protein StabilityPublished by Elsevier BV ,1998
- The Upregulation of p27Kip1 by Rapamycin Results in G1 Arrest in Exponentially Growing T-Cell LinesBlood, 1998
- Rapamycin Resistance Tied to Defective Regulation of p27Kip1Molecular and Cellular Biology, 1996
- Structure-activity studies of rapamycin analogs: evidence that the C-7 methoxy group is part of the effector domain and positioned at the FKBP12-FRAP interfaceCell Chemical Biology, 1995
- RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORsCell, 1994
- Rapamycin Inhibits p34cdc2 Expression and Arrests T Lymphocyte Proliferation at the G1/S TransitionAnnals of the New York Academy of Sciences, 1993
- CYCLOSPORINE AND RAPAMYCIN AFFECT PROTEIN KINASE C INDUCTION OF THE INTRACELLULAR ACTIVATION SIGNAL, ACTIVATOR OF DNA REPLICATIONTransplantation, 1993
- Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinaseNature, 1992
- Atomic Structure of FKBP-FK506, an Immunophilin-Immunosuppressant ComplexScience, 1991